国际皮肤性病学杂志    2005 31 (2): 72-74   ISSN: 2096-5540  CN: 32-1880/R   银屑病性关节炎系统治疗的进展 刘荣, 张福仁, 李中伟 山东省皮肤病性病防治研究所 济南 250022 收稿日期 2004-07-13  修回日期 null  网络版发布日期 null 参考文献  [1] Kane D, Stafford L, Bresnihan B,et al. A prospective, clinical and radiological study of early psoriatic arthritis: an early synovitis clinic experience. Rheumatology (Oxford), 2003, 42:1460-1468. [2] Pipitone N, Kingsley GH, Manzo A, et al. Current concepts and new developments in the treatment of psoriatic arthritis. Rheumatology (Oxford), 2003, 42:1138-1148. [3] Sarzi-Puttini P, Santandrea S, Boccassini L,et al. The role of NSAIDs in psoriatic arthritis: evidence from a controlled study with nimesulide. Clin Exp Rheumatol, 2001,19(1 Suppl 22):S17-S20. [4] Salvarani C, Cantini F, Olivieri I. Disease-modifying antirheumatic drug therapy for psoriatic arthritis. Clin Exp Rheumatol, 2002, 20(6 Suppl 28):S71-S75. [5] Rahman P, Gladman DD, Cook RJ, et al. The use of sulfasalazine in psoriatic arthritis: a clinic experience. J Rheumatol, 1998, 25:1957-1961. [6] Raffayova H, Rovensky J, Malis F. Treatment with cyclosporin in patients with psoriatic arthritis: results of clinical assessment. Int J Clin Pharmacol Res, 2000, 20:1-11. [7] Cosottini M, Lazzarotti G, Ceravolo R, et al. Cyclosporine-related posterior reversible encephalopathy syndrome (PRES) in non-transplant patient: a case report and literature review. Eur J Neurol, 2003, 10:461-462. [8] Liang GC, Barr WG. Open trial of leflunomide for refractory psoriasis and psoriatic arthitis. J Clin Rheumatol,2001, 7: 366-370. [9] Schrader P, Mooser G, Peter RU, et al.Preliminary results in the therapy of psoriatic arthritis with mycophenolate mofetil. Z Rheumatol, 2002, 61:545-550. [10] Takada K, Danning CL, Kuroiwa T, et al. Lymphocyte depletion with fludarabine in patients with psoriatic arthritis: clinical and immunological effects. Ann Rheum Dis, 2003, 62:1112-1115. [11] Ujfalussy I, Koo E, Sesztak M,et al. Termination of disease-modifying antirheumatic drugs in rheumatoid arthritis and in psoriatic arthritis. A comparative study of 270 cases. Z Rheumatol, 2003, 62:155-160. [12] Ciompi ML, Bazzichi L, Marotta G, et al. Tigason (etretinate) treatment in psoriatic arthritis. Int J Tissue React, 1988, 10:25-27. [13] Mease PJ, Goffe BS, Metz J,et al. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet, 2000, 356:385-390. [14] Galadari H, Fuchs B, Lebwohl M. Newly available treatments for psoriatic arthritis and their impact on skin psoriasis. Int J Dermatol, 2003, 42:231-237. [15] Culy CR, Keating GM. Spotlight on etanercept in rheumatoid arthritis, psoriatic arthritis and juvenile rheumatoid arthritis. BioDrugs, 2003, 17:139-145. [16] Culy CR, Keating GM. Etanercept: an updated review of its use in rheumatoid arthritis, psoriatic arthritis and juvenile rheumatoid arthritis. Drugs, 2002,62 :2493-2537. [17] Antoni C, Dechant C, Hanns-Martin Lorenz PD, et al. Open-label study of infliximab treatment for psoriatic arthritis: clinical and magnetic resonance imaging measurements of reduction of inflammation. Arthritis Rheum, 2002, 47:506-512. [18] Provenzano G, Termini A, Le Moli C, et al. Efficacy of infliximab in psoriatic arthritis resistant to treatment with disease modifying antirheumatic drugs: an open pilot study. Ann Rheum Dis, 2003, 62:680-681. [19] Feletar M, Brockbank JE, Schentag CT, et al. Treatment of refractory psoriatic arthritis with infliximab: a 12 month observational study of 16 patients.Ann Rheum Dis, 2004, 63:156-161. [20] Kraan MC, van Kuijk AW, Dinant HJ, et al. Alefacept treatment in psoriatic arthritis: reduction of the effector T cell population in peripheral blood and synovial tissue is associated with improvement of clinical signs of arthritis. Arthritis Rheum, 2002, 46:2776-2784. [21] Utset TO,Auger JA,Peace D, et al. Modified anti-CD3 therapy in psoriatic arthritis:a phase Ⅰ/Ⅱclinical trial. J Rheumatol,2002,29:1907-1913. [22] Rubbert-Roth A, Perniok A. Interleukin-1 receptor antagonist anakinra (Kineret) for treatment of rheumatic arthritis. Z Rheumatol, 2003, 62:367-377. 通讯作者: